Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decentralized Trial of BI 1358894 in MDD
NCT04423757Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bi 1358894 in major depressive disorder (MDD), sponsored by Boehringer Ingelheim. Started Jun 2020; status: terminated.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04423757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423757.